LP
CRNX icon

Longaeva Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Longaeva Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
+58,388
New +$2.17M 0.05% 248

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Longaeva Partners's CRNX Position: Q2 2026 in Review

Longaeva Partners opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 58,388 shares worth $2.18M. The stake represents 0.05% of the portfolio and ranks #248 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Longaeva Partners held 58,388 shares of Crinetics Pharmaceuticals worth $2.18M as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Longaeva Partners position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.05% of Longaeva Partners's portfolio in Q2 2026, its #248 holding.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.